

## DAFTAR PUSTAKA

1. Busetta A, Bono F. Demographic aspects of aging. Caruso C, Candore G, editors. Human Aging. London: Elsevier; 2021. 13–34.
2. Undang-Undang Republik Indonesia No 13 Tahun 1998 tentang Kesejahteraan Usia Lanjut.
3. Girsang APL, Ramadani KD, Nugroho SW, Sulistyowati NP, Putrianti R, Wilson H. Statistik penduduk lanjut usia 2021. Mustari AS, Santoso B, Maylasari I, Sinang R, editor. Badan Pusat Statistik Indonesia. Jakarta; 2021.
4. Pasco AJ. Age-related changes in muscle and bone. Duque G, editor. Osteosarcopenia: Bone, Muscle and Fat Interactions. Melbourne: Springer International Publishing; 2019. 45-72
5. Setiati S, Dwimartutie N. Sarkopenia. Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam Jilid 1 Edisi VI. Jakarta: Interna Publshing; 2016. 3719 – 27.
6. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a Quantitative Review. *Front Physiol.* 2012; 3(260): 1-18.
7. Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, et al. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. *J Gerontol A Biol Sci Med Sci.* 2001; 56(5): 209–17.
8. Lynch GS. Sarcopenia age-related muscle wasting and weakness. Dordrecht: Springer Netherlands; 2011. 1-8.
9. Diz JBM, Leopoldino AAO, Moreira B de S, Henschke N, Dias RC, Pereira LSM, et al. Prevalence of sarcopenia in older Brazilians: A systematic review and meta-analysis: Prevalence of sarcopenia in Brazil. *Geriatr Gerontol Int.* 2017; 17(1): 5–16.
10. Pasco JA, Brennan Olsen SL. Low lean tissue mass and physical performance as markers of sarcopenia in older men and women. *J Gerontol Geriatr Res.* 2016; 5(3): 1-4

11. Vitriana, Defi IR, Irawan GN, Setiabudiawan B, et al. Prevalensi sarkopenia pada lansia di komunitas (Community Dwelling) berdasarkan dua nilai cut-off parameter diagnosis. *Maj Kedokt Bdg.* 2016; 48(3): 164–70.
12. Widajanti N, Ichwani J, Dharmanta RS, Firdausi H, Haryono Y, Yulianti E, et al. Sarcopenia and frailty profile in the elderly community of surabaya: A descriptive study. *Acta Med Indones.* 2020; 52(1): 5-10.
13. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States: Economic cost of sarcopenia. *J Am Geriatr Soc.* 2004; 52 (1): 80–5.
14. Gillespie ND, Witham MD, Struthers AD. Chronic Heart Failure. Fillit H, Rockwood K, Young J, editors. *Brocklehurst's textbook of geriatric medicine and gerontology.* Eighth edition. Philadelphia, PA: Elsevier, Inc; 2017. 265-77.
15. Hasil utama riset kesehatan dasar 2018. Badan Penelitian dan Pengembangan Kesehatan, Kementrian Kesehatan Republik Indonesia.
16. Lena A, Anker MS, Springer J. Muscle wasting and sarcopenia in heart failure—The current state of science. *Int J Mol Sci.* 2020; 21(6549): 1-17.
17. Pinijmung P, Yuenyongchaiwat K, Buakhamsri A. Prevalence and impact of sarcopenia in heart failure: A cross-sectional study. *Open Cardiovasc Med J.* 2022; 16: 1-6.
18. Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, et al. Sarcopenia and heart failure. *Nutrients.* 2020; 12(211): 1-15.
19. Gospodinov K, Todorova Y, Tisheva S. The impact of age-related sarcopenia on survival and mortality in patients with chronic heart failure. *J IMAB - Annu Proceeding Sci Pap.* 2022; 28(3): 4474–9.
20. Chang JS. *Irisin as a biomarker of sarcopenia.* Seoul: Department of Medicine, Yonsei University; 2014.
21. Aryana IGPS, Putrawan IB, Purnami NKR, Kuswardhani RAT, Astika IN, Suastika K, et al. Irisin rendah dalam serum sebagai faktor risiko sarkopenia pada lanjut usia. *J Penyakit Dalam Indones.* 2021; 7(4): 215-20.
22. Aryana IGPS, Hapsari AAAR, Kuswardhani RAT. Myokine regulation as marker of sarcopenia in elderly. *Mol Cell Biomed Sci.* 2018; 2(2): 38-47.

23. Colaianni G, Colucci S, Cinti S, Grano M. The myokine irisin recapitulates the effect of physical activity on bone and muscle tissues. *JGG*. 2016; 64(5): 92-6.
24. Barbalho SM, Flato UAP, Tofano RJ, Goulart R de A, Guiguer EL, Detregiachi CRP, et al. Physical exercise and myokines: Relationships with sarcopenia and cardiovascular complications. *Int J Mol Sci*. 2020; 21(3607): 1-15.
25. Silvestrini A, Bruno C, Vergani E, Venuti A, Favuzzi AMR, Guidi F, et al. Circulating irisin levels in heart failure with preserved or reduced ejection fraction: A pilot study. Lionetti V, editor. *PLOS ONE*. 2019; 14(1): 1-7.
26. Matsuo Y, Gleitsmann K, Mangner N, Werner S, Fischer T, Bowen TS, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines: FNDC5 expression in skeletal muscle in chronic heart failure. *J Cachexia Sarcopenia Muscle*. 2015; 6: 62–72.
27. Lecker SH, Zavin A, Cao P, Arena R, Allsup K, Daniels KM, et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. *Circ Heart Fail*. 2012; 5: 812–8.
28. Liu C, Wei A, Wang T. Irisin, an Effective Treatment for Cardiovascular Diseases? *J Cardiovasc Dev Dis*. 2022; 9(9): 305.
29. Paula JA de, Wamser EL, Gomes ARS, Valderramas SR, Cardoso Neto J, Schieferdecker MEM. Análise de métodos para detectar sarcopenia em idosos independentes da comunidade. *Rev Bras Geriatr E Gerontol*. 2016; 19(2): 235–46.
30. Cruz-Jentoft AJ, Montero BE. Sarcopenia. Roller-Wirnsberger R, Singler K, Polidori MC, editors. *Learning geriatric medicine: A study guide for medical students*. Cham: Springer International Publishing; 2018. 99-114.
31. Kalinkovich A, Livshits G. Sarcopenia – The search for emerging biomarkers. *Ageing Res Rev*. 2015; 22: 58–71.

32. Patel HP, Clift E, Lewis L, Cooper C. Epidemiology of sarcopenia and frailty. Dionyssiotis Y, editor. Frailty and sarcopenia - Onset, development and clinical challenges. InTech; 2017. 1-22.
33. Santilli V. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014; 11(3): 177-80.
34. Wu CH, Chen KT, Hou MT, Chang YF, Chang CS, Liu PY, et al. Prevalence and associated factors of sarcopenia and severe sarcopenia in older Taiwanese living in rural community: The Tianliao old people study 04: Sarcopenia in community-dwelling older Taiwanese. Geriatr Gerontol Int. 2014; 14(1): 69–75.
35. Ogawa S, Yakabe M, Akishita M. Age-related sarcopenia and its pathophysiological bases. Inflamm Regen. 2016; 36(17): 1-6.
36. Gomes MJ, Martinez PF, Damatto L, Cezar MDM, Lima ARR, Okoshi MP. Skeletal muscle aging: influence of oxidative stress and physical exercise. Impact jour. 2017; 8(12): 1-13.
37. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2006; 908(1): 244–54.
38. Ali S, Garcia JM. Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options. 2014; 60(4): 294-305.
39. Bahat G, Tufan A, Tufan F, Kilic C, Akpınar TS, Kose M, et al. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin Nutr. 2016; 35(6): 1557–63.
40. Sergi G, De Rui M, Stubbs B, Veronese N, Manzato E. Measurement of lean body mass using bioelectrical impedance analysis: a consideration of the pros and cons. Aging Clin Exp Res. 2017; 29: 591–7.
41. Gonzalez MC, Heymsfield SB. Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: what are we really estimating?: Editorial. J Cachexia Sarcopenia Muscle. 2017; 8: 187–9.
42. Brotto M, Abreu EL. Sarcopenia: Pharmacology of today and tomorrow. J Pharmacol Exp Ther. 2012; 343: 540–6.

43. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. 2010; 39: 412–23.
44. Bhasin S, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA, et al. Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. *J Am Geriatr Soc*. 2020;68:1410–8.
45. Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argilés JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. *Am J Physiol-Endocrinol Metab*. 2009; 296: 191–202.
46. Marzetti E, Carter CS, Wohlgemuth SE, Lees HA, Giovannini S, Anderson B, et al. Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction. *Mech Ageing Dev*. 2009; 130: 272–80.
47. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014; 15: 95–101.
48. Bohannon RW. Are Hand-grip and knee extension strength reflective of a common construct?. *Percept Mot Skills*. 2012; 114: 514–8.
49. White TA, LeBrasseur NK. Myostatin and sarcopenia: Opportunities and challenges - A mini-review. *Gerontology*. 2014; 60: 289–93.
50. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021; 42: 3599–726.
51. Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. *Heart Fail Clin*. 2012; 8: 143–64.
52. Lakatta EG, Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part II: The aging heart in health: Links to heart disease. *Circulation*. 2003; 107: 346–54.
53. Mirza M, Strunets A, Shen WK, Jahangir A. Mechanisms of arrhythmias and conduction disorders in older adults. *Clin Geriatr Med*. 2012; 28: 555–73.

54. Marzetti E, Csiszar A, Dutta D, Balagopal G, Calvani R, Leeuwenburgh C. Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. *Am J Physiol-Heart Circ Physiol*. 2013; 305: 459–76.
55. Bernhard D, Laufer G. The aging cardiomyocyte: A mini-review. *Gerontology*. 2008; 54: 24–31.
56. Parks RJ, Fares E, MacDonald JK, Ernst MC, Sinal CJ, Rockwood K, et al. A procedure for creating a frailty index based on deficit accumulation in aging mice. *J Gerontol Ser A*. 2012; 67: 217–27.
57. Chen W, Frangogiannis NG. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. *Heart Fail Rev*. 2010; 15: 415–22.
58. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart failure with preserved ejection fraction: Molecular pathways of the aging myocardium. *Circ Res*. 2014; 115: 97–107.
59. Feridooni HA, Dibb KM, Howlett SE. How cardiomyocyte excitation, calcium release and contraction become altered with age. *J Mol Cell Cardiol*. 2015; 83: 62–72.
60. Kaila K, Haykowsky MJ, Thompson RB, Paterson DI. Heart failure with preserved ejection fraction in the elderly: scope of the problem. *Heart Fail Rev*. 2012; 17: 555–62.
61. Fleg JL, Strait J. Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease. *Heart Fail Rev*. 2012; 17: 545–54.
62. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction. *J Am Coll Cardiol*. 2013; 62: 263–71.
63. Park M, Sweeney G. Direct effects of adipokines on the heart: focus on adiponectin. *Heart Fail Rev*. 2013; 18: 631–44.
64. Boxer RS, Shah KB, Kenny AM. Frailty and prognosis in advanced heart failure. *Curr Opin Support Palliat Care*. 2014; 8: 25–9.
65. Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Mitochondrial function as a therapeutic target in heart failure. *Nat Rev Cardiol*. 2017; 14: 238–50.

66. Lee JF, Barrett-O'Keefe Z, Nelson AD, Garten RS, Ryan JJ, Nativi-Nicolau JN, et al. Impaired skeletal muscle vasodilation during exercise in heart failure with preserved ejection fraction. *Int J Cardiol.* 2016; 211: 14–21.
67. İlhan B, Bahat G, Erdoğan T, Kiliç C, Karan MA. Anorexia is independently associated with decreased muscle mass and strength in community dwelling older adults. *J Nutr Health Aging.* 2019; 23: 202–6.
68. Schaap LA, Pluijm SMF, Deeg DJH, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: Associations with 5-year change in muscle mass and muscle strength. *J Gerontol A Biol Sci Med Sci.* 2009; 64: 1183–9.
69. Filippatos GS, Kanatselos C, Manolatos DD, Vougas B, Sideris A, Kardara D, et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. *Int J Cardiol.* 2003; 90: 107–13.
70. Saitoh M, Ishida J, Doehner W, von Haehling S, Anker MS, Coats AJS, et al. Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. *Int J Cardiol.* 2017; 238: 5–11.
71. Curcio F, Liguori I, Cellulare M, Sasso G, Della-Morte D, Gargiulo G, et al. Physical activity scale for the elderly (PASE) score is related to sarcopenia in noninstitutionalized older adults. *J Geriatr Phys Ther.* 2019; 42: 130–5.
72. dos Santos MR, Saitoh M, Ebner N, Valentova M, Konishi M, Ishida J, et al. Sarcopenia and endothelial function in patients with chronic heart failure: Results from the studies investigating comorbidities aggravating heart failure (SICA-HF). *J Am Med Dir Assoc.* 2017; 18: 240–5.
73. Nichols S, O'Doherty AF, Taylor C, Clark AL, Carroll S, Ingle L. Low skeletal muscle mass is associated with low aerobic capacity and increased mortality risk in patients with coronary heart disease - a CARE CR study. *Clin Physiol Funct Imaging.* 2019; 39: 93–102.
74. Carbone S, Billingsley HE, Rodriguez-Miguel P, Kirkman DL, Garten R, Franco RL, et al. Lean mass abnormalities in heart failure: The role of sarcopenia, sarcopenic obesity, and cachexia. *Curr Probl Cardiol.* 2020; 45: 100417.

75. He N, Zhang Y, Zhang L, Zhang S, Ye H. Relationship between sarcopenia and cardiovascular diseases in the elderly: An overview. *Front Cardiovasc Med.* 2021; 8(743710): 1-12.
76. Korta P, Pocheć E, Mazur-Biały A. Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases. *Medicina (Mex).* 2019; 55(8): 485.
77. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1- $\alpha$ -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature.* 2012; 481: 463–8.
78. Maak S, Norheim F, Drevon CA, Erickson HP. Progress and challenges in the biology of FNDC5 and Irisin. *Endocr Rev.* 2021; 42: 436–56.
79. Waseem R, Shamsi A, Mohammad T, Hassan MdI, Kazim SN, Chaudhary AA, et al. FNDC5/Irisin: Physiology and pathophysiology. *Molecules.* 2022; 27: 1118.
80. Ma C, Ding H, Deng Y, Liu H, Xiong X, Yang Y. Irisin: A new code uncover the relationship of skeletal muscle and cardiovascular health during exercise. *Front Physiol.* 2021; 12(620608): 1-12.
81. Moreno M, Moreno-Navarrete JM, Serrano M, Ortega F, Delgado E, Sanchez-Ragnarsson C, et al. Circulating Irisin Levels Are Positively Associated with Metabolic Risk Factors in Sedentary Subjects. Tauler P, editor. *PLoS One.* 2015; 10(4): e0124100.
82. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. *Metabolism.* 2012; 61(12): 1725–38.
83. Ozbay S, Ulupınar S, Şebin E, Altınkaynak K. Acute and chronic effects of aerobic exercise on serum irisin, adropin, and cholesterol levels in the winter season: Indoor training versus outdoor training. *Chin J Physiol.* 2020; 63(1): 21-6.



84. Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, et al. Irisin Mediates Effects on Bone and Fat via  $\alpha V$  Integrin Receptors. *Cell*. 2018; 175(7): 1756-68.
85. Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson MM, et al. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. *Cell Metab*. 2015; 22(4):734–40.
86. Lagzdina R, Rumaka M, Gersone G, Tretjakovs P. Circulating Irisin in Healthy Adults: Changes after Acute Exercise, Correlation with Body Composition, and Energy Expenditure Parameters in Cross-Sectional Study. *Medicina (Mex)*. 2020;56:274.
87. Biniaminov N, Bandt S, Roth A, Haertel S, Neumann R, Bub A. Irisin, physical activity and fitness status in healthy humans: No association under resting conditions in a cross-sectional study. Staiger H, editor. *PLOS ONE*. 2018;13:e0189254.
88. Anastasilakis AD, Polyzos SA, Saridakis ZG, Kynigopoulos G, Skouvaklidou EC, Molyvas D, et al. Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. *J Clin Endocrinol Metab*. 2014;99:3247–55.
89. Rabiee F, Lachinani L, Ghaedi S, Nasr-Esfahani MH, Megraw TL, Ghaedi K. New insights into the cellular activities of Fndc5/Irisin and its signaling pathways. *Cell Biosci*. 2020; 10: 51.
90. Zhang Y, Song H, Zhang Y, Wu F, Mu Q, Jiang M, et al. Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p. *J Am Heart Assoc*. 2016; 5(9): e004031.
91. Bashar SM, Samir El-sherbeiny SM, Boraie MZ. Correlation between the blood level of irisin and the severity of acute myocardial infarction in exercise-trained rats. *J Basic Clin Physiol Pharmacol*. 2018; 30(1): 59–71.
92. Liao Q, Qu S, Tang L xun, Li L peng, He D fen, Zeng C yu, et al. Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis. *Acta Pharmacol Sin*. 2019; 40(10): 1314–21.

93. Zhu G, Wang J, Song M, Zhou F, Fu D, Ruan G, et al. Irisin Increased the Number and Improved the Function of Endothelial Progenitor Cells in Diabetes Mellitus Mice. *J Cardiovasc Pharmacol.* 2016; 68(1): 67–73.
94. Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on FNDC5 gene expression and irisin release in human skeletal muscle and adipose tissue: *in vivo* and *in vitro* studies: Human FNDC5/irisin in prediabetes, type 2 diabetes and exercise. *J Physiol.* 2014; 592: 1091–107.
95. Planella-Farrugia C, Comas F, Sabater-Masdeu M, Moreno M, Moreno-Navarrete JM, Rovira O, et al. Circulating Irisin and Myostatin as markers of muscle strength and physical condition in elderly subjects. *Front Physiol.* 2019; 10(871): 1-12.
96. Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. *J Clin Invest.* 2018; 128: 3716–26.
97. Zhao Q, Sun Q, Zhou L, Liu K, Jiao K. Complex regulation of mitochondrial function during cardiac development. *J Am Heart Assoc.* 2019; 8(012731): 1-12.
98. Ho MY, Wang CY. Role of Irisin in myocardial infarction, heart failure, and cardiac hypertrophy. *Cells.* 2021; 10(2103): 1-12.
99. Sobieszek G, Powrózek T, Mazurek M, Skwarek-Dziekanowska A, Małeczka-Massalska T. Electrical and hormonal biomarkers in cachectic elderly women with chronic heart failure. *J Clin Med.* 2020;9(1021): 1-12.
100. Ho MY, Wen MS, Yeh JK, Hsieh IC, Chen CC, Hsieh MJ, et al. Excessive irisin increases oxidative stress and apoptosis in murine heart. *Biochem Biophys Res Commun.* 2018; 503: 2493–8.
101. Shen S, Gao R, Bei Y, Li J, Zhang H, Zhou Y, et al. Serum Irisin predicts mortality risk in acute heart failure patients. *Cell Physiol Biochem.* 2017; 42: 615–22.
102. Shin MJ, Jeon YK, Kim IJ. Testosterone and Sarcopenia. *World J Mens Health.* 2018;36:192.
103. Pelegrini A, Mazo GZ, Pinto ADA, Benedetti TRB, Silva DAS, Petroski EL. Sarcopenia: prevalence and associated factors among elderly from a Brazilian

- capital. *Fisioter Em Mov* [Internet]. 2018 [cited 2023 Dec 4];31. Available from:[http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S0103-51502018000100201&lng=en&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-51502018000100201&lng=en&tlng=en)
- 104.Ho AW, Lee MM, Chan EW, Ng HM, Lee C, et al. Prevalence of pre-sarcopenia and sarcopenia in Hong Kong Chinese geriatric patients with hip fracture and its correlation with different factors. *Hong Kong Med J* [Internet]. 2015 [cited 2023 Dec 4]; Available from: <http://www.hkmj.org/abstracts/v22n1/23.htm>
- 105.Sun DS, Lee H, Yim HW, Won HS, Ko YH. The impact of sarcopenia on health-related quality of life in elderly people: Korean National Health and Nutrition Examination Survey. *Korean J Intern Med.* 2019;34:877–84.
- 106.Han DS, Chang KV, Li CM, Lin YH, Kao TW, Tsai KS, et al. Skeletal muscle mass adjusted by height correlated better with muscular functions than that adjusted by body weight in defining sarcopenia. *Sci Rep.* 2016;6:19457.
- 107.Vikberg S, Sörlén N, Brandén L, Johansson J, Nordström A, Hult A, et al. Effects of Resistance Training on Functional Strength and Muscle Mass in 70-Year-Old Individuals With Pre-sarcopenia: A Randomized Controlled Trial. *J Am Med Dir Assoc.* 2019;20:28–34.
- 108.Liguori I, Russo G, Aran L, Bulli G, Curcio F, Della-Morte D, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. *Clin Interv Aging.* 2018;Volume 13:913–27.
- 109.Fukuoka Y, Narita T, Fujita H, Morii T, Sato T, Sassa MH, et al. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. *J Diabetes Investig.* 2019;10:322–30.
- 110.Farmer RE, Mathur R, Schmidt AF, Bhaskaran K, Fatemifar G, Eastwood SV, et al. Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank. *J Am Heart Assoc.* 2019;8:e011638.

111. Lutski M, Weinstein G, Tanne D, Goldbourt U. Overweight, Obesity, and Late-Life Sarcopenia Among Men With Cardiovascular Disease, Israel. *Prev Chronic Dis.* 2020;17:200167
112. Umehara T, Kaneguchi A, Yamasaki T, Katayama N, Kawakami W, Kuwahara D, et al. Reduced upper and lower limb muscle strengths without reduced skeletal muscle in elderly patients with heart failure. *J Rural Med.* 2023;18:8–14.
113. Blanquet M, Massoulié G, Boirie Y, Guiguet-Auclair C, Mulliez A, Anker S, et al. Handgrip strength to screen early-onset sarcopenia in heart failure. *Clin Nutr ESPEN.* 2022;50:183–90.
114. Wang Y, Pu X, Zhu Z, Sun W, Xue L, Ye J. Handgrip strength and the prognosis of patients with heart failure: A meta-analysis. *Clin Cardiol.* 2023;46:1173–84.
115. Gasser B, Wagner J, Schoch R, Schmidt-Trucksäss A. Skeletal muscle and heart failure – What is the relationship between central versus peripheral affections? *Nutr Metab Cardiovasc Dis.* 2023;33:1907–13.
116. Lopez PD, Nepal P, Akinlonu A, Nekkalapudi D, Kim K, Cativo EH, et al. Low Skeletal Muscle Mass Independently Predicts Mortality in Patients with Chronic Heart Failure after an Acute Hospitalization. *Cardiology.* 2019;142:28–36.
117. Bijlsma AY, Meskers CGM, Ling CHY, Narici M, Kurrle SE, Cameron ID, et al. Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. *AGE.* 2013;35:871–81.
118. Cao M, Lian J, Lin X, Liu J, Chen C, Xu S, et al. Prevalence of sarcopenia under different diagnostic criteria and the changes in muscle mass, muscle strength, and physical function with age in Chinese old adults. *BMC Geriatr.* 2022;22:889
119. Yin J, Lu X, Qian Z, Xu W, Zhou X. New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure. *Theranostics.* 2019;9:4019–29.

120. Kono Y, Izawa H, Aoyagi Y, Ishikawa A, Sugiura T, Mori E, et al. The difference in determinant factor of six-minute walking distance between sarcopenic and non-sarcopenic elderly patients with heart failure. *J Cardiol*. 2020;75:42–6.
121. Sakuragi S, Ichikawa K, Mori A. Determinant of Gait Speed in Elderly Patients With Heart Failure. *J Card Fail*. 2016;22:S191.
122. Bekfani T, Bekhite Elsaied M, Derlien S, Nisser J, Westermann M, Nietzsche S, et al. Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail*. 2020;13:e007198.
123. Park HS, Kim HC, Zhang D, Yeom H, Lim SK. The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. *Endocrine*. 2019;64:341–8.
124. Oguz A, Sahin M, Tuzun D, Kurutas EB, Ulgen C, Bozkus O, et al. Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study. *Medicine (Baltimore)*. 2021;100:e26529.
125. Chang JS, Kim TH, Nguyen TT, Park K, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. *Geriatr Gerontol Int*. 2017;17:2266–73.
126. Zhao M, Zhou X, Yuan C, Li R, Ma Y, Tang X. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. *Sci Rep*. 2020;10:16093.
127. Berezin AA, Fushtey IM, Pavlov SV, Berezin AE. Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus. *Mol Biomed*. 2022;3:34.
128. Abd El-Mottaleb NA, Galal HM, El Maghraby KM, Gadallah AI. Serum irisin level in myocardial infarction patients with or without heart failure. *Can J Physiol Pharmacol*. 2019;97:932–8.